Endocytosis of ATB^0,+(SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic cancer

References

• Le Q-V, Yang G, Wu Y, et al. Nanomaterials for modulating innate immune cells in cancer immunotherapy. Asian J Pharm Sci. 2019 [2019 Jan 01];14(1):16–29.
   PubMed Web of Science ®Google Scholar
• Bi H, Xue J, Jiang H, et al. Current developments in drug delivery with thermosensitive liposomes. Asian J Pharm Sci. 2019 [2019 July 01];14(4):365–379.
   PubMed Web of Science ®Google Scholar
• Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: focus on recent advances. Asian J Pharm Sci. 2019 [2019 Sep 01];14(5):480–496.
   PubMed Web of Science ®Google Scholar
• Kou L, Sun R, Bhutia YD, et al. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery. Expert Opin Drug Deliv. 2018 Sep;15(9):869–879.
   PubMed Web of Science ®Google Scholar
• Luo Q, Gong P, Sun M, et al. Transporter occluded-state conformation-induced endocytosis: amino acid transporter ATB(0,+)-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy. J Control Release. 2016 Dec 10;243:370–380.
   PubMed Web of Science ®Google Scholar
• Mignani S, Rodrigues J, Roy R, et al. Exploration of biomedical dendrimer space based on in-vitro physicochemical parameters: key factor analysis (Part 1). Drug Discov Today. 2019 May;24(5):1176–1183.
   PubMed Web of Science ®Google Scholar
• Kou L, Sun R, Xiao S, et al. Ambidextrous approach to disrupt redox balance in tumor cells with increased ROS production and decreased GSH synthesis for cancer therapy. ACS Appl Mater Interfaces. 2019 [2019 July 31];11(30):26722–26730.
   PubMed Web of Science ®Google Scholar
• Yao Q, Dai Z, Hoon Choi J, et al. Building stable MMP2-responsive multifunctional polymeric micelles by an all-in-one polymer–lipid conjugate for tumor-targeted intracellular drug delivery. ACS Appl Mater Interfaces. 2017 [2017 Oct 27];9(38):32520–32533.
   PubMed Web of Science ®Google Scholar
• Yao Q, Choi JH, Dai Z, et al. Improving tumor specificity and anticancer activity of dasatinib by dual-targeted polymeric micelles. ACS Appl Mater Interfaces. 2017 [2017 Oct 25];9(42):36642–36654.
   PubMed Web of Science ®Google Scholar
• Kou L, Yao Q, Sun M, et al. Cotransporting Ion is a trigger for cellular endocytosis of transporter-targeting nanoparticles: a case study of high-efficiency SLC22A5 (OCTN2)-mediated carnitine-conjugated nanoparticles for oral delivery of therapeutic drugs. Adv Healthc Mater. 2017 [2017 Sep 01];6(17):1700165.
   Web of Science ®Google Scholar
• Han L, Hu L, Liu F, et al. Redox-sensitive micelles for targeted intracellular delivery and combination chemotherapy of paclitaxel and all-trans-retinoid acid. Asian J Pharm Sci. 2019 [2019 Sep 01];14(5):531–542.
   PubMed Web of Science ®Google Scholar
• Yao Q, Kou L, Tu Y, et al. MMP-responsive ‘Smart’ drug delivery and tumor targeting. Trends Pharmacol Sci. 2018 Aug;39(8):766–781.
   PubMed Web of Science ®Google Scholar
• Kou L, Bhutia YD, Yao Q, et al. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Front Pharmacol. 2018;9:27.
   PubMed Web of Science ®Google Scholar
• Soe ZC, Poudel BK, Nguyen HT, et al. Folate-targeted nanostructured chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to colorectal cancer cells. Asian J Pharm Sci. 2019 [2019 Jan 01];14(1):40–51.
   PubMed Web of Science ®Google Scholar
• Kou L, Sun R, Ganapathy V, et al. Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5). Expert Opin Ther Targets. 2018 Aug;22(8):715–726.
   PubMed Web of Science ®Google Scholar
• Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chem Rev. 2017 Oct 11;117(19):12133–12164.
   PubMed Web of Science ®Google Scholar
• Unsoy G, Gunduz U. Smart drug delivery systems in cancer therapy. Curr Drug Targets. 2018 Feb 8;19(3):202–212.
   PubMed Web of Science ®Google Scholar
• Sheikhpour M, Barani L, Kasaeian A. Biomimetics in drug delivery systems: A critical review. J Control Release. 2017 May 10;253:97–109.
   PubMed Web of Science ®Google Scholar
• Kou L, Yao Q, Sivaprakasam S, et al. Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB(0,+) to deliver chemotherapeutic agents for colon cancer therapy. Drug Deliv. 2017 Nov;24(1):1338–1349.
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009 Jan;121(1):29–40.
   PubMed Web of Science ®Google Scholar
• Bhutia YD, Babu E, Prasad PD, et al. The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. Asian J Pharm Sci. 2014 [2014 Dec 01];9(6):293–303.
   Google Scholar
• Bhutia YD, Babu E, Ramachandran S, et al. Amino Acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015 May 1;75(9):1782–1788.
   PubMed Web of Science ®Google Scholar
• Bhutia YD, Ganapathy V. Glutamine transporters in mammalian cells and their functions in physiology and cancer. Biochim Biophys Acta. 2016 Oct;1863(10):2531–2539.
   PubMed Web of Science ®Google Scholar
• Guo Q, Li C, Zhou W, et al. GLUT1-mediated effective anti-miRNA21 pompon for cancer therapy. Acta Pharm Sin B. 2019 Jul;9(4):832–842.
   PubMed Web of Science ®Google Scholar
• Li L, Di X, Wu M, et al. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: toward a novel active targeting strategy in breast cancer therapy. Nanomed. 2017 Apr;13(3):987–998.
   PubMed Web of Science ®Google Scholar
• Li L, Di X, Zhang S, et al. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloids Surf B Biointerfaces. 2016 May 1;141:260–267.
   PubMed Web of Science ®Google Scholar
• Li J, Guo Y, Kuang Y, et al. Choline transporter-targeting and co-delivery system for glioma therapy. Biomaterials. 2013 Dec;34(36):9142–9148.
   PubMed Web of Science ®Google Scholar
• Du Y, Tian C, Wang M, et al. Dipeptide-modified nanoparticles to facilitate oral docetaxel delivery: new insights into PepT1-mediated targeting strategy. Drug Deliv. 2018 Nov;25(1):1403–1413.
   PubMed Web of Science ®Google Scholar
• Kou L, Hou Y, Yao Q, et al. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2. Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):1605–1616.
   PubMed Web of Science ®Google Scholar
• Karunakaran S, Ramachandran S, Coothankandaswamy V, et al. SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem. 2011 Sep 9;286(36):31830–31838.
   PubMed Web of Science ®Google Scholar
• Luo Q, Yang B, Tao W, et al. ATB(0,+) transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes. Biomater Sci. 2017 Jan 31;5(2):295–304.
   PubMed Web of Science ®Google Scholar
• Kou L, Sun J, Zhai Y, et al. The endocytosis and intracellular fate of nanomedicines: implication for rational design. Asian J Pharm Sci. 2013 [2013 Feb 01];8(1):1–10.
   Google Scholar
• Wang Z, Chi D, Wu X, et al. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB0,+ for efficient tumor therapy. J Control Release. 2019 [2019 Oct 30];316:22–33.
   Web of Science ®Google Scholar
• Coothankandaswamy V, Cao S, Xu Y, et al. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol. 2016 Dec;173(23):3292–3306.
   PubMed Web of Science ®Google Scholar